Compare Commvault Systems Inc (CVLT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Commvault Systems (CVLT) trades at $151.00, up 0.48% on the day, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. The company maintains robust profitability metrics, including an 81.09% gross margin and 32.77% ROE, though valuation ratios like a P/E of 96.73 appear elevated. Positive news includes AWS competency achievements and new board appointments, reinforcing its market position.

The outlook remains favorable given earnings momentum and institutional confidence, but high valuation multiples pose a risk if growth moderates. Revenue is projected to rise to $1.2 billion in 2026, though net margin may compress. With no sell ratings and a consensus price target of $156.55, upside potential exists, but investors should monitor competitive pressures and execution on guidance.

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.